Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Rating of “Hold” by Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has received a consensus recommendation of “Hold” from the six analysts that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $9.40.

A number of brokerages have weighed in on RXRX. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Jefferies Financial Group dropped their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC decreased their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th.

Insider Buying and Selling

In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $8.13, for a total value of $48,780.00. Following the completion of the sale, the chief operating officer now owns 535,457 shares of the company’s stock, valued at $4,353,265.41. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total transaction of $76,351.49. Following the transaction, the director now owns 7,089,007 shares of the company’s stock, valued at $47,283,676.69. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the sale, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $4,353,265.41. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 201,682 shares of company stock worth $1,332,933. 15.75% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new stake in Recursion Pharmaceuticals during the third quarter worth about $25,000. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $26,000. GAMMA Investing LLC increased its position in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares in the last quarter. Amalgamated Bank raised its holdings in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares during the period. Finally, San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals during the third quarter valued at approximately $69,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $6.61 on Wednesday. The stock’s 50-day moving average price is $6.73 and its 200 day moving average price is $7.76. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.57 billion, a PE ratio of -4.13 and a beta of 0.80. Recursion Pharmaceuticals has a 52-week low of $4.97 and a 52-week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm had revenue of $14.42 million for the quarter, compared to analysts’ expectations of $11.96 million. During the same quarter in the previous year, the company posted ($0.38) EPS. The firm’s quarterly revenue was up 30.9% compared to the same quarter last year. As a group, equities research analysts forecast that Recursion Pharmaceuticals will post -1.58 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.